Compare VERU & MKTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | MKTW |
|---|---|---|
| Founded | 1971 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 39.1M |
| IPO Year | 1990 | N/A |
| Metric | VERU | MKTW |
|---|---|---|
| Price | $2.65 | $16.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $22.50 | $20.00 |
| AVG Volume (30 Days) | ★ 203.5K | 13.2K |
| Earning Date | 02-12-2026 | 02-27-2026 |
| Dividend Yield | N/A | ★ 4.94% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.55 |
| Revenue | N/A | ★ $342,206,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.34 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.10 | $9.08 |
| 52 Week High | $14.20 | $21.74 |
| Indicator | VERU | MKTW |
|---|---|---|
| Relative Strength Index (RSI) | 60.36 | 59.44 |
| Support Level | $2.27 | $14.60 |
| Resistance Level | $2.49 | $15.95 |
| Average True Range (ATR) | 0.17 | 0.61 |
| MACD | 0.04 | 0.18 |
| Stochastic Oscillator | 90.60 | 93.64 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.